These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18537808)

  • 1. [Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial].
    Liakishev AA
    Kardiologiia; 2008; 48(5):72. PubMed ID: 18537808
    [No Abstract]   [Full Text] [Related]  

  • 2. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
    Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
    Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk.
    Liebson PR; Amsterdam EA
    Prev Cardiol; 2009; 12(1):43-50. PubMed ID: 19301691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.
    Sleight P
    J Hypertens Suppl; 2009 Jul; 27(5):S23-9. PubMed ID: 19587551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
    Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
    Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
    Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
    [No Abstract]   [Full Text] [Related]  

  • 8. Telmisartan in high-risk cardiovascular patients.
    Weber MA
    Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan, ramipril, or both in patients at high risk of vascular events.
    Büchner N; Banas B; Krämer BK
    N Engl J Med; 2008 Jul; 359(4):426. PubMed ID: 18650521
    [No Abstract]   [Full Text] [Related]  

  • 10. ONTARGET: questions asked, questions answered.
    Weber MA
    J Clin Hypertens (Greenwich); 2008 Jun; 10(6):427-30. PubMed ID: 18550931
    [No Abstract]   [Full Text] [Related]  

  • 11. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
    Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
    Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
    Burnier M; Waeber B; Hess O; Lüscher T
    Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371
    [No Abstract]   [Full Text] [Related]  

  • 14. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Cohn JN
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan, ramipril, or both in patients at high risk for vascular events.
    ; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
    N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is therapy of people with chronic kidney disease ONTARGET?
    Mann JF; Tobe S; Teo KK; Yusuf S
    Nephrol Dial Transplant; 2010 Jan; 25(1):42-4. PubMed ID: 19854846
    [No Abstract]   [Full Text] [Related]  

  • 17. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.
    Petrovic I; Petrovic D; Vukovic N; Zivanovic B; Dragicevic J; Vasiljevic Z; Babic R
    J Int Med Res; 2005; 33 Suppl 1():39A-49A. PubMed ID: 16222899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
    Düsing R; Nitschmann S
    Internist (Berl); 2008 Sep; 49(9):1137-40. PubMed ID: 18665340
    [No Abstract]   [Full Text] [Related]  

  • 19. ONTARGET should not be over interpreted.
    Abutaleb N
    Nephrol Dial Transplant; 2010 Jan; 25(1):44-7. PubMed ID: 19934088
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.